Home     Media Contacts     Links     Sitemap     MRMC globe4.gif     MEDCOM globe4.gif     Army globe4.gif     AKO globe4.gif     CTC globe4.gif     FAQ          
HOME Sunday, October 21 2018

WRAIR Researchers Present Annual Vaccine Conference in Thailand



COL Jerome Kim, MHRP Deputy Director and Dr. Barton Haynes, chair of the RV144 Scientific Steering Committee, presented results of the RV144 correlates studies, which provide "new clues" to how the RV144 vaccine regimen may have provided protection from HIV. The AIDS Vaccine conference is the largest scientific gathering of top scientists, policy makers, community advocates and funders who focus exclusively on AIDS vaccine research.

Two years after the results were announced, RV144 is generating new data and scientific momentum among the HIV research community. This year much of the focus at the conference was on the correlates work that has occurred since RV144 concluded in Thailand.

The annual AIDS meeting is hosted by the Global HIV Vaccine Enterprise, an alliance of independent research, funding, advocacy and stakeholder organizations dedicated to developing an AIDS vaccine.

To learn more about MHRP, please visit their website:

Following below is a list of MHRP presentations, as well as collaborator presentations on the RV144 lab studies:

Plenary Sessions

Moving Forward from RV144: An Industrial Perspective Sanjay Gurunathan, sanofi Pasteur

Progress Towards an HIV Vaccine – Lessons Learned from HIV Prevention Carl Dieffenbach, Division of AIDS, NIAID

Thailand’s Contribution to HIV Vaccine Research and Development Punnee Pitisuttithum, Mahidol University

Update on RV144: Correlates, Sieve Analysis, and Clinical Development Jerome Kim, MHRP

Case Control Study of the RV144 Trial for Immune Correlates: The Analysis and Way Forward Barton Haynes, Duke Human Vaccine Institute

Vaccines Beyond RV144 Poxvirus Vector-Based HIV Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois

Oral Presentations

Cell-Mediated Immune Responses After DNA Delivered by Either Biojector or Electroporation and Boosted with a Heterologous Insert Recombinant Poxvirus JR Currier

Extended Evaluation of Volunteers Who Become HIV-1 Infected During Participation in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX® B/E S Rerks-Ngarm

Inhibition of Human Immunodeficiency Virus Type 1 Infection of Human Monocyte-Derived Macrophages by Anti-Lipid and Anti-MPER Monoclonal Antibodies M Rao

Lymphocyte Dynamics in Acute HIV-1 Infection: RV217-The Early Capture HIV Cohort Study (ECHO) L Eller

The RV144 Vaccine Induced CD4+ T Cells Producing Th1 and Th2 Cytokines with Proliferative Potential S DeRosa

Influence of NK Cells and NK Cell Receptor Polymorphisms in the Assessment of HIV-1 Neutralization BK Brown

The Thai Phase III Clinical Trial (RV144) Induces the Generation of Antibodies That Target a Conserved Region Within the V2 Loop of GP120 N Karasavvas

ADCC Titers to HIV-Infected Cells Are Detectable in the Majority of Vaccine Recipients in the RV144 Trial MD Alpert

Surface Plasmon Resonance Analysis of Anti-gp120 V2-Specific IgG Antibodies Generated in the RV144 Thai Trial EA Billings

V2-Reactive Antibodies in RV144 Vaccinees' Plasma S Zolla-Pazner

A DNA Prime/Protein Boost Vaccine Leads to Higher B-Cell Responses than a Vector Prime/Protein Boost or DNA Prime/Vector Boost Regimens N Frahm

Sequence Analysis of HIV-1 Breakthrough Infections in the RV144 Trial Morgane Rolland, U.S. Military HIV Research Program

Sieve Analysis of RV144 Paul Edlefsen, Fred Hutchinson Cancer Research

Defining the Spectrum of Vaccine Induced Humoral Responses Georgia Tomaras, Duke University


Early Cytokine and Chemokine Patterns During Acute HIV Infection B. Tassaneetrithep

Significant Contribution of Subtype G to HIV-1 Genetic Complexity in Nigeria RA Heipertz

Evaluation of Peripheral Blood and Mucosal HIV-1 Viral Load In Volunteers Who Became HIV-1 Infected During Participation In The Thai Phase III Trial S Rerks-Ngarm

Safety and Reactogenicity of ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Prime-Boost Vaccination Regimen in a Community-Based Efficacy Trial P Pitisuttithum

Construction and Characterization of HIV-1 Mosaic Modified Vaccinia Ankara (MVA) Vaccines L Eller

Characterization of the Immune Response in the Gut Mucosa and Peripheral Blood in Acute HIV- infected Thai Individuals A Schuetz

Challenges in Consenting Sex Workers, Transgenders and Men Who Have Sex with Men into an HIV Acute Infection Study in Pattaya, Thailand P Charuthamrong

B Cell Depletion in HIV-1 Subtype A Infected Ugandan Adults: Relationship to CD4 Count, Viral Load and Humoral Immune Responses PO Oballah

Antigen-Specific Enhancement of Natural Human IgG Antibodies to Lipids Induced by a Liposomal Vaccine Containing Lipid A and a Protein Antigen GR Matyas

Abnormal Liver Function During Acute HIV Infection Correlates with Fiebig Stage and Systemic Inflammation J Fletcher

Risk Behavior and Demographic Characteristics of Infected vs Non-Infected Participants in RV217d, a Study in At-Risk Populations in Pattaya, Thailand A Bolen Valenzuela

Role of Antibody and Complement in Neutralization of Trans Infection by Erythrocyte-bound HIV-1 Z Beck

Generating Viruses Matching RV144 Vaccine Components to Explore Efficacy A Chenine

Characterization of Cellular Immune Responses Elicited by Ad35-GRIN/ENV and MVA Construct Prime-Boost Regimens J Cox

Liposomes Containing Glucosyl Ceramide and the Adjuvant Monophosphoryl Lipid A Specifically Bind T4 Bacteriophage: A Self-Assembling Nanocarrier KK Peachman

Pre-Conference Symposia

Moving Forward Together: Research Literacy and Community Engagement in 2011 and Beyond

Gathering Sexual Risk Information in HIV Biomedical Prevention Trials – An Offering of Best Practices

Last Modified Date: 09-September-2016

This Web site provides an introduction to the U.S. Army Medical Research and Materiel Command (USAMRMC) and contains official Government information. Its use is intended for members of the general public, news media and Army Medical Department beneficiaries.
Please address questions or concerns about this website to the Public Affairs Office via e-mail or by telephone at 301-319-9471.